Kite (KITE) volatility flat into presenting interim results from ZUMA-1 pivotal trial at ASH meeting )

November 21, 2016 12:40 PM EST

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Kite Pharma (NASDAQ: KITE) December call option implied volatility is at 60, January is at 61; compared to its 52-week range of 51 to 119 after announcing that data from the interim analysis of the pivotal ZUMA-1 trial of KTE-C19 in patients with chemorefractory aggressive non-Hodgkin lymphoma have been accepted as an oral late-breaking presentation at the American Society of Hematology, or ASH, 58th Annual Meeting in San Diego, CA, on December 6, 2016.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Related Entities

Options

Add Your Comment